Cargando…

α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis

Systemic sclerosis is a connective tissue disease of unknown origin that is characterized by immune system abnormalities, vascular damage, and extensive fibrosis of the skin and visceral organs. α2-antiplasmin is known to be the main plasmin inhibitor and has various functions such as cell different...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanno, Yosuke, Shu, En
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953682/
https://www.ncbi.nlm.nih.gov/pubmed/35330147
http://dx.doi.org/10.3390/life12030396
_version_ 1784675911043383296
author Kanno, Yosuke
Shu, En
author_facet Kanno, Yosuke
Shu, En
author_sort Kanno, Yosuke
collection PubMed
description Systemic sclerosis is a connective tissue disease of unknown origin that is characterized by immune system abnormalities, vascular damage, and extensive fibrosis of the skin and visceral organs. α2-antiplasmin is known to be the main plasmin inhibitor and has various functions such as cell differentiation and cytokine production, as well as the regulation of the maintenance of the immune system, endothelial homeostasis, and extracellular matrix metabolism. The expression of α2-antiplasmin is elevated in dermal fibroblasts from systemic sclerosis patients, and the blockade of α2-antiplasmin suppresses fibrosis progression and vascular dysfunction in systemic sclerosis model mice. α2-antiplasmin may have promise as a potential therapeutic target for systemic sclerosis. This review considers the role of α2-antiplasmin in the progression of systemic sclerosis.
format Online
Article
Text
id pubmed-8953682
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89536822022-03-26 α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis Kanno, Yosuke Shu, En Life (Basel) Review Systemic sclerosis is a connective tissue disease of unknown origin that is characterized by immune system abnormalities, vascular damage, and extensive fibrosis of the skin and visceral organs. α2-antiplasmin is known to be the main plasmin inhibitor and has various functions such as cell differentiation and cytokine production, as well as the regulation of the maintenance of the immune system, endothelial homeostasis, and extracellular matrix metabolism. The expression of α2-antiplasmin is elevated in dermal fibroblasts from systemic sclerosis patients, and the blockade of α2-antiplasmin suppresses fibrosis progression and vascular dysfunction in systemic sclerosis model mice. α2-antiplasmin may have promise as a potential therapeutic target for systemic sclerosis. This review considers the role of α2-antiplasmin in the progression of systemic sclerosis. MDPI 2022-03-09 /pmc/articles/PMC8953682/ /pubmed/35330147 http://dx.doi.org/10.3390/life12030396 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kanno, Yosuke
Shu, En
α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis
title α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis
title_full α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis
title_fullStr α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis
title_full_unstemmed α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis
title_short α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis
title_sort α2-antiplasmin as a potential therapeutic target for systemic sclerosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953682/
https://www.ncbi.nlm.nih.gov/pubmed/35330147
http://dx.doi.org/10.3390/life12030396
work_keys_str_mv AT kannoyosuke a2antiplasminasapotentialtherapeutictargetforsystemicsclerosis
AT shuen a2antiplasminasapotentialtherapeutictargetforsystemicsclerosis